HTD 4010

Drug Profile

HTD 4010

Alternative Names: HTD4010

Latest Information Update: 08 Aug 2016

Price : $50

At a glance

  • Originator HighTide Biopharma
  • Class Antihyperglycaemics; Cytokines; Peptide fragments
  • Mechanism of Action Transcription factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 28 Jul 2016 HighTide BioPharma plans a phase II trial for Type-2 diabetes
  • 01 Mar 2016 HighTide Biopharma completes a phase I trial in Type-2 diabetes mellitus (In volunteers) in Australia (Parenteral) (NCT02538848)
  • 31 Aug 2015 Preclinical trials in Type-2 diabetes mellitus in Australia (Parenteral) before August 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top